A J Muir

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Diagnosis and treatment of chronic hepatitis C infection
    Keyur Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27707, USA
    BMJ 332:1013-7. 2006
  2. pmc Reducing medication regimen complexity: a controlled trial
    A J Muir
    Division of Gastroenterology, Duke University Medical Center, Durham, NC 27710, USA
    J Gen Intern Med 16:77-82. 2001
  3. ncbi request reprint Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection
    A J Muir
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Viral Hepat 13:322-8. 2006
  4. doi request reprint Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response
    Andrew J Muir
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC 27715, USA
    Hepatology 54:1538-46. 2011
  5. ncbi request reprint Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites
    Andrew J Muir
    Division of Gastroenterology, Duke University, Durham, NC, USA
    N Engl J Med 350:2265-71. 2004
  6. doi request reprint Telaprevir for the treatment of chronic hepatitis C infection
    Andrew J Muir
    Division of Gastroenterology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    Expert Rev Anti Infect Ther 9:1105-14. 2011
  7. doi request reprint Hepatitis C treatment among racial and ethnic groups in the IDEAL trial
    A J Muir
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC 27701, USA
    J Viral Hepat 18:e134-43. 2011
  8. doi request reprint Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection
    Andrew J Muir
    Division of Gastroenterology, Duke University, Durham, NC 27701, USA
    Hepatology 52:822-32. 2010
  9. ncbi request reprint A survey of current liver biopsy practice patterns
    Andrew J Muir
    Division of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Gastroenterol 35:86-8. 2002
  10. ncbi request reprint A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection
    Andrew J Muir
    Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Gastroenterol 34:268-71. 2002

Research Grants

Collaborators

Detail Information

Publications44

  1. pmc Diagnosis and treatment of chronic hepatitis C infection
    Keyur Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27707, USA
    BMJ 332:1013-7. 2006
  2. pmc Reducing medication regimen complexity: a controlled trial
    A J Muir
    Division of Gastroenterology, Duke University Medical Center, Durham, NC 27710, USA
    J Gen Intern Med 16:77-82. 2001
    ..To determine if a visual intervention (medication grid) delivered to physicians can reduce medication regimen complexity...
  3. ncbi request reprint Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection
    A J Muir
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Viral Hepat 13:322-8. 2006
    ..These data provide a basis for further study of interferon gamma-1b in patients with chronic fibrosing liver disease...
  4. doi request reprint Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response
    Andrew J Muir
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC 27715, USA
    Hepatology 54:1538-46. 2011
    ..The overall relapse rate was 16% (13/83). Adverse events were similar to those in previous trials with telaprevir, with 9% of patients discontinuing due to an adverse event (most commonly rash and anemia)...
  5. ncbi request reprint Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites
    Andrew J Muir
    Division of Gastroenterology, Duke University, Durham, NC, USA
    N Engl J Med 350:2265-71. 2004
    ..The increased prevalence of infection with hepatitis C virus (HCV) genotype 1, which has a lower response rate than other genotypes, has been suggested as the cause...
  6. doi request reprint Telaprevir for the treatment of chronic hepatitis C infection
    Andrew J Muir
    Division of Gastroenterology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    Expert Rev Anti Infect Ther 9:1105-14. 2011
    ..Viral resistance can develop during treatment with telaprevir, and patients will need to be educated on their role in adherence to minimize the risk of resistance and improve their chances of cure of HCV infection...
  7. doi request reprint Hepatitis C treatment among racial and ethnic groups in the IDEAL trial
    A J Muir
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC 27701, USA
    J Viral Hepat 18:e134-43. 2011
    ..Therefore, decisions regarding HCV treatment should consider the predictive value of the early on-treatment response, not just baseline characteristics, such as race and ethnicity...
  8. doi request reprint Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection
    Andrew J Muir
    Division of Gastroenterology, Duke University, Durham, NC 27701, USA
    Hepatology 52:822-32. 2010
    ....
  9. ncbi request reprint A survey of current liver biopsy practice patterns
    Andrew J Muir
    Division of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Gastroenterol 35:86-8. 2002
    ..To survey clinicians regarding current liver biopsy practice patterns...
  10. ncbi request reprint A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection
    Andrew J Muir
    Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Gastroenterol 34:268-71. 2002
    ..To assess the number of chronic hepatitis C patients eligible for therapy...
  11. doi request reprint Telaprevir for previously treated chronic HCV infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, USA
    N Engl J Med 362:1292-303. 2010
    ..Patients with genotype 1 hepatitis C virus (HCV) who do not have a sustained response to therapy with peginterferon alfa and ribavirin have a low likelihood of success with retreatment...
  12. doi request reprint Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    Dongliang Ge
    Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
    Nature 461:399-401. 2009
    ....
  13. ncbi request reprint Treatment of hepatitis C in special populations
    Meera Ramamurthy
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Clin Liver Dis 10:851-65. 2006
    ..These groups generally were not included in the early large clinical trials of HCV treatment. This article reviews recent findings in these patients groups and examines future directions...
  14. pmc Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response
    P J Clark
    Duke Clinical Research Institute, Duke University, Durham, NC 27715, USA
    J Viral Hepat 19:332-40. 2012
    ..LDL-C remains significantly associated with SVR for heterozygous IL28B genotype patients, where LDL-C and HCV RNA burden may identify those patients with high or low likelihood of cure with pegIFN/RBV therapy...
  15. doi request reprint Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Gastroenterology 139:120-9.e18. 2010
    ..We sought to confirm the polymorphism's clinical relevance by intention-to-treat analysis evaluating on-treatment virologic response and SVR...
  16. pmc Gastroesophageal reflux and altered motility in lung transplant rejection
    J M Castor
    Division of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Neurogastroenterol Motil 22:841-50. 2010
    ..Although additional prospective studies are needed, fundoplication appears useful in the prevention or treatment of post-transplant BOS...
  17. ncbi request reprint A case of electrical storm in a liver transplant patient
    T D Schmidt
    Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Transplant Proc 35:1437-8. 2003
    ....
  18. ncbi request reprint Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients
    Z F Gellad
    Department of Medicine, Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Transpl Infect Dis 9:276-80. 2007
    ..Exposure to corticosteroids was significantly associated with an increased risk of relapse and may warrant a longer treatment course...
  19. pmc Disparities in liver transplantation before and after introduction of the MELD score
    Cynthia A Moylan
    Division of Gastroenterology, Duke University Medical Center, PO Box 3913, Durham, NC 27710, USA
    JAMA 300:2371-8. 2008
    ..Before MELD, black patients were more likely to die or become too sick to undergo liver transplantation compared with white patients. Little information exists regarding sex and access to liver transplantation...
  20. pmc Uncertainty, symptoms, and quality of life in persons with chronic hepatitis C
    Donald E Bailey
    Duke University School of Nursing, DUMC PO Box 3322, Durham, NC 27710, USA
    Psychosomatics 50:138-46. 2009
    ..Chronic hepatitis C (CHC) is the most common blood-borne infection in the United States, but little is known about illness uncertainty in these patients...
  21. doi request reprint Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University, Durham, NC 27715, USA
    N Engl J Med 360:1827-38. 2009
    ..Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV RNA levels in early studies...
  22. ncbi request reprint An examination of factors predicting prioritization for liver transplantation
    Andrew J Muir
    Division of Gastroenterology, Duke University Medical Center, Durham, NC 27710, USA
    Liver Transpl 8:957-61. 2002
    ..In conclusion, these data show the wide range of practice patterns with the use of status 2A, and these findings suggest that certain patient groups might have received preference in the previous liver transplant allocation system...
  23. doi request reprint Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center
    Janice H Jou
    Duke University Medical Center, Box 3913, Durham, NC 27710, USA
    Dig Dis Sci 55:3591-6. 2010
    ..We assessed if patients evaluated for hepatocellular carcinoma are being diagnosed by surveillance, the proportion of patients meeting Milan criteria at diagnosis, and rates of liver transplantation...
  24. doi request reprint Hepatitis C transmission, prevention, and treatment knowledge among patients with HIV
    Rae Jean Proeschold-Bell
    Duke University Global Health Institute and Duke University Center for Health Policy, Durham, NC 27708, USA
    South Med J 103:635-41. 2010
    ..Little is known about the HCV knowledge of PLWHA...
  25. doi request reprint Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era
    Carla W Brady
    Veterans Affairs Medical Center, Durham, NC, USA
    Liver Transpl 14:228-34. 2008
    ..06, 1.86) emerged as a predictor of increased odds of de novo HCC. A significant proportion of patients listed for OLT develop de novo HCC. Identifying predictors of HCC in these patients may facilitate timely HCC screening and diagnosis...
  26. ncbi request reprint De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant
    Michael A Heneghan
    Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA
    Am J Transplant 3:634-8. 2003
    ..No viable tumor was identified in the explanted liver. This case establishes that long-term complications associated with PSC and biliary-enteric surgery such as CCA may become apparent in new grafts post-transplant...
  27. doi request reprint Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 361:580-93. 2009
    ..Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared...
  28. pmc Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin
    Jeanette J McCarthy
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27708, USA
    Gastroenterology 138:2307-14. 2010
    ..We investigated the association between the polymorphism rs12979860 and treatment response in a diverse cohort of chronic HCV patients...
  29. doi request reprint The use of mind-body medicine and prayer among adult patients with chronic hepatitis C
    Jacqueline A Richmond
    Gastroenterology Hepatology Research Program, Duke Clinical Research Institute, Durham, North Carolina, USA
    Gastroenterol Nurs 33:210-6. 2010
    ..To provide patient-centered healthcare, health providers need to be aware of the alternative support strategies, including mind-body medicine, used by patients...
  30. ncbi request reprint Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection
    Steven L Condron
    Division of Gastroenterology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA
    Transplantation 80:145-8. 2005
    ..Recent studies from selected centers have suggested that older donor age is associated with worse outcomes after transplantation for HCV...
  31. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Gastroenterology 139:1181-9. 2010
    ..We aimed to replicate this finding in an independent cohort from the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C and to investigate the effects of these variants beyond week 4...
  32. pmc Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection
    Josephine H Li
    Institute for Genome Sciences and Policy, Durham, NC 27708, USA
    Hepatology 51:1904-11. 2010
    ..06), and apolipoprotein E (P = 0.01) were slightly lower in the rs12979860 CC genotype group, whereas levels of high-density lipoprotein cholesterol (P = 0.78) and apolipoprotein C-III (P = 0.74) did not vary by rs12979860 genotype...
  33. doi request reprint ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C
    Jacques Fellay
    Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
    Nature 464:405-8. 2010
    ..Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV...
  34. ncbi request reprint Clinical utilization of digital rectal examination and fecal occult blood testing upon hospital admission
    Charles D Scales
    Division of Gastroenterology, Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    J Clin Gastroenterol 40:913-8. 2006
    ..The objective of our investigation was to examine the clinical utilization of digital rectal examination (DRE) and fecal occult blood testing (FOBT) at hospital admission...
  35. ncbi request reprint Treatment of hepatitis C in special populations
    Cynthia A Moylan
    Division of Gastroenterology and Duke Clinical Research Institute, Duke University Medical Center, Box 3913, Durham, NC 27710, USA
    Clin Liver Dis 9:567-77, v. 2005
    ..This article reviews recent findings from research in these patient groups and examines future directions and treatment trials...
  36. ncbi request reprint Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis
    Michael A Heneghan
    Department of Gastroenterology, Duke University Medical Center, Durham, NC 27710, USA
    J Hepatol 45:584-91. 2006
    ..Our aims were to evaluate the role of TPMT genotyping and phenotyping and to examine 6-TG and 6-MMP metabolite levels in patients with AIH...
  37. ncbi request reprint Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?
    Keyur Patel
    Hepatology 38:21-4. 2003
  38. ncbi request reprint Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin
    Vijayan Balan
    Division of Transplantation Medicine, Mayo Clinic Hospital, 5777 E Mayo Boulevard, Phoenix, AZ 85054, USA
    Am J Gastroenterol 100:299-307. 2005
    ..The purpose of this study was to describe the time course and extent of hemoglobin (Hb) changes and the erythropoietic response to PEG-IFN/RBV-induced anemia...
  39. ncbi request reprint Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients
    Keyur Patel
    Hepatology 37:1222; author reply 1222-3. 2003
  40. ncbi request reprint Growth factors during HCV therapy may be "cost-effective", but are they "effective"?
    Andrew J Muir
    Hepatology 44:1400-3. 2006
  41. ncbi request reprint Acute HCV: the early bird catches the virus
    Andrew J Muir
    Gastroenterology 122:1176-7; discussion 1177-8. 2002
  42. ncbi request reprint HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis
    Carla W Brady
    Hepatology 42:496-7; author reply 497. 2005
  43. ncbi request reprint In the clinic. Hepatitis C
    Janice H Jou
    Ann Intern Med 148:ITC6-1-ITC6-16. 2008
  44. doi request reprint Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemia
    Karen R Canlas
    Division of Gastroenterology and Hepatology, Duke University Medical Center, Durham, NC 27705, USA
    J Clin Gastroenterol 42:844-8. 2008
    ..We aimed to evaluate the ability of capsule endoscopy (CE) to detect small intestine (SI) lesions, especially SI varices, in patients with intrahepatic cirrhosis, portal hypertension (PHTN), and chronic anemia...

Research Grants2

  1. Interferon-gamma To Treat Chronic HCV Infection
    Andrew Muir; Fiscal Year: 2002
    ..Secondary endpoints include the biochemical response, inflammatory and regulatory cytokine levels, and quality of life during treatment. ..